Private equity fundraising appears to be gaining momentum, with several healthcare-focused firms announcing sizeable closes in recent weeks. The blog explores where capital is being directed.
Yesterday I attended Cannabis Europa at the Barbican in London. This is an annual conference focused on Europe’s medicinal cannabis industry held by Prohibition Partners (a B2B market intelligence and events business). The overarching theme from panel discussions was that the nascent cannabis industry being built in Europe is different from the “wild west” one that has taken root in the US, where the line between medicinal and recreational use tends to be seen as little more than a bureaucratic formality.
It’s no longer enough to focus only on treating illness more efficiently. The real value in healthcare is shifting earlier in the journey, long before someone becomes a patient, and that shift is increasingly where investment attention is going too.
This week we report on the intervention by the UK’s Competition and Markets Authority (CMA) into acquisitions made by US healthcare REIT Welltower in the UK’s care market.
This week I participated in a webinar hosted by the International Federation of Health Plans (iFHP), the main global trade body for private health insurers. The purpose of this was to present and discuss the Special Report we published on private medical insurance (PMI) in February, to an audience of iFHP’s members.
The UK’s private dental sector is facing a period of significant regulatory and structural change, and it could affect investors and businesses across the industry.
In late March, as part of HBI 2026, global medtech firm GE HealthCare hosted a visit to its Buc site in France, one of its main R&D and manufacturing centres for mammography, interventional systems and AI software. The group included ten global healthcare CEOs and a private equity partner. I also had the opportunity to join. The visit offered a closer look at how large-scale medical innovation is developed and delivered.
This week we have published our third annual Special Report on European healthcare property investment. As well as an update on the general state of investment activity in the market, this report features more case studies than last year’s report, and an even more in-depth discussion on the on-going dearth of new developments across most of the continent, and what investors and operators can do to ameliorate the situation.
At HBI’s 2026 conference last month I chaired a panel entitled ‘Agentic AI beyond the scribe: What's next for healthcare?’. This included case studies from Oskari Eskola, CEO of Finnish digital health group Beehealthy, and David Reich, President of New York non-profit hospital Mount Sinai Hospital, who each presented multiple new AI tools they’re deploying to improve care quality and efficiency.
HBI attended the McDermott Will & Schulte life sciences conference this week. The big questions weren’t if deals would happen, but how fast, how risky and on whose terms.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
